^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:FF-10101 (FLT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

    Published date:
    05/19/2021
    Excerpt:
    The FF-10101-01 FLT3 inhibitor has shown activity in pts with refractory/relapsed AML, including those with activating FLT3-ITD mutations resistant to gilteritinib and other FLT3 kinase inhibitors.
    DOI:
    10.1200/JCO.2021.39.15_suppl.7008
    Trial ID:
    NCT03194685
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2021
    Title:

    PHASE 1 FIRST-IN-HUMAN STUDY OF IRREVERSIBLE FLT3 INHIBITOR FF-10101-01 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

    Published date:
    05/12/2021
    Excerpt:
    The FF-10101-01 FLT3 inhibitor has shown activity in pts with refractory/relapsed AML, including those with activating FLT3-ITD mutations resistant to gilteritinib and other FLT3 kinase inhibitors.